Funding & Awards
Forecasted
Cure HHT's Funding & Awards program supports research and innovation to advance scientific understanding and treatment of hereditary hemorrhagic telangiectasia.
Funder: Cure HHT
Due Dates (Anticipated): January 2027 (annual application deadline, projected)
Funding Amounts: Typical awards $30,000–$50,000; total annual funding varies by program.
Summary: Supports research, collaboration, and innovation to advance treatments and improve outcomes for the hereditary hemorrhagic telangiectasia (HHT) community.
Key Information: This is a forecasted opportunity; deadlines and funding details may change—check the program page for updates.
Description
The Cure HHT Funding & Awards program is a cornerstone initiative designed to propel research, foster collaboration, and raise awareness in the hereditary hemorrhagic telangiectasia (HHT) community. As the only global organization solely focused on HHT, Cure HHT funds high-impact research projects in basic, clinical, translational, and genetic science, with the goal of uncovering disease mechanisms, improving current treatments, and ultimately finding a cure. The program encompasses a range of opportunities, including seed research grants, young investigator awards, clinical science research grants, travel grants, and support for scientific conferences.
